DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Authors: Matthew James Verheyden, Medical Student University of Notre Dame Australia, Sydney, NSW, Australia; Claudia Hadlow, Medical Student University of Notre Dame Australia, Sydney, NSW, Australia; Dr Tevi Wain, Consultant Dermatologist, The Skin Hospital, Westmead, NSW, Australia. DermNet NZ Editor in Chief: Adjunct A/Prof. Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. November 2019.
The auriculotemporal syndrome is characterised by sweating, flushing, and warming over the preauricular area (the front of the ear) and temporal areas (the region of the face behind the eyes) in response to a gustatory stimulus .
Lucja Frey, a Polish physician and neurologist, first described the auriculotemporal syndrome in 1923, leading to the alternative name, Frey syndrome . It is also known as gustatory hyperhidrosis, Baillarger syndrome, and Dupuy syndrome.
The precise incidence of the auriculotemporal syndrome is unknown . Patients often underreport the incidence due to subclinical symptoms .
The auriculotemporal syndrome most frequently occurs as a complication of surgical removal of the parotid gland (parotidectomy) with estimated rates of 4–96% [5,6,7]. Males and females are affected equally.
Infrequently, the auriculotemporal syndrome is observed in infants and children following forceps-assisted delivery . A rare familial, bilateral auriculotemporal syndrome without trauma has been reported .
The cause of the syndrome involves aberrant regeneration of the auriculotemporal branch of the mandibular nerve following injury, infection, or surgery in the vicinity of the parotid gland (the salivary gland in front of the ears) .
The auriculotemporal nerve ordinarily provides sympathetic innervation to the sweat glands and parasympathetic innervation to the salivary gland.
With trauma, the parasympathetic fibres may become misdirected and regenerate along the pathway of the sympathetic nerve establishing a connection with the sweat glands and blood vessels of the skin . Thus, instead of saliva production, sweating and flushing occur with a gustatory stimulus .
Damage to the ganglions within the cervical sympathetic chain may also cause auriculotemporal syndrome .
Symptoms are often apparent within the first year after parotidectomy. However, delayed recognition is not unusual . Once symptoms commence, there is often a gradual increase in severity for several months, and they then remain relatively constant thereafter.
Symptoms are triggered by chewing (gustatory sweating) or the sight, smell, or thought of food. They include:
Symptoms are variable in severity ranging from barely perceivable to rather troublesome; 15% of patients rate their symptoms as severe and are especially concerned by excessive sweating.
The auriculotemporal syndrome is associated with significant psychosocial morbidity [1, 14]. See Psychosocial factors in dermatology.
The diagnosis of the auriculotemporal syndrome is based on the recognition of characteristic symptoms .
The Minor starch-iodine test can be used to confirm hyperhidrosis . Iodine solution is applied to the affected area, allowed to dry, and is followed by the application of starch. Subsequently, the patient is given a stimulus to promote salivation, often an acidic food. Marked discolouration in the affected region indicates disproportionate sweating.
Other conditions that may be considered in a patient with symptoms suggesting auriculotemporal syndrome include:
Treatment of auriculotemporal syndrome is targeted at symptom control . Patients with mild symptoms do not require treatment.
A Cochrane review was unable to establish the efficacy and safety of various treatments for the auriculotemporal syndrome, due to an absence of randomised control trials .
Pharmacological options to treat troublesome auriculotemporal syndrome include:
Surgical management is reserved for severe and refractory auriculotemporal syndrome and may involve:
The auriculotemporal syndrome tends to be benign in infants with spontaneous resolution occurring in the majority .
Spontaneous resolution occurs in 5% of adults with the auriculotemporal syndrome. The pharmacological treatments described above generally control symptoms short term. Repeated injections of botulinum toxin A are required every 4–6 months, or earlier if symptoms recur [22,28]. Rarely, refractory cases require surgical management .
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.